Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.351
Neutral
RSI(14)
43.380
Neutral
STOCH(KDJ)(9,3,3)
55.787
Sell
ATR(14)
0.998
High Vlolatility
CCI(14)
-17.288
Neutral
Williams %R
58.403
Sell
TRIX(12,20)
-0.720
Sell
StochRSI(14)
0.000
Sell
Forte Biosciences Inc
FBRXView Detailed Chart
6.050USD
-0.830-12.06%
Close 04/23, 16:00（ET）Quotes delayed by 15 min
38.68MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-12.06%
5 Days
-16.67%
1 Month
-25.95%
6 Months
+25.26%
Year to Date
-73.36%
1 Year
-67.24%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
3
analysts
BUY
Current Rating
59.000
Target Price
761.31%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
109
Total
4
Median
6
Average
Company name
Ratings
Analysts
Forte Biosciences Inc
FBRX
3
Lyft Inc
LYFT
47
Apple Inc
AAPL
47
GE Vernova Inc
GEV
32
UnitedHealth Group Inc
UNH
30
Cigna Group
CI
26
1
2
3
...
22
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Sell
Moving Average
Indicators
Value
Direction
MA5
6.902
Sell
MA10
6.278
Sell
MA20
6.649
Sell
MA50
7.620
Sell
MA100
13.313
Sell
MA200
10.874
Sell
News
More news coming soon, stay tuned...
Company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Company codeFBRX
CompanyForte Biosciences Inc
CEODr. Paul A. Wagner, Ph.D.
Website
